Halozyme Therapeutics (HALO) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Halozyme Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.02B

Latest Revenue (Q)

$290.08M

Main Segment (Y)

Royalty

Main Geography (Y)

SWITZERLAND

Halozyme Therapeutics Revenue by Period

Halozyme Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$1.02B	22.44%
2023-12-31	$829.25M	25.62%
2022-12-31	$660.12M	48.91%
2021-12-31	$443.31M	65.67%
2020-12-31	$267.59M	36.53%
2019-12-31	$195.99M	29.06%
2018-12-31	$151.86M	-52.04%
2017-12-31	$316.61M	115.84%
2016-12-31	$146.69M	8.61%
2015-12-31	$135.06M	79.28%
2014-12-31	$75.33M	37.47%
2013-12-31	$54.80M	29.47%
2012-12-31	$42.33M	-24.54%
2011-12-31	$56.09M	311.67%
2010-12-31	$13.62M	-0.35%
2009-12-31	$13.67M	55.99%
2008-12-31	$8.76M	130.66%
2007-12-31	$3.80M	287.02%
2006-12-31	$981.75K	671.76%
2005-12-31	$127.21K	100.00%
2004-12-31	-	-100.00%
2003-12-31	$25.70K	-70.71%
2002-12-31	$87.77K	255.56%
2001-12-31	$24.68K	-

Halozyme Therapeutics generated $1.02B in revenue during NA 2024, up 22.44% compared to the previous quarter, and up 518.04% compared to the same period a year ago.

Halozyme Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$290.08M	25.39%
2024-06-30	$231.35M	18.11%
2024-03-31	$195.88M	-14.85%
2023-12-31	$230.04M	6.48%
2023-09-30	$216.03M	-2.26%
2023-06-30	$221.04M	36.32%
2023-03-31	$162.14M	-10.66%
2022-12-31	$181.50M	-13.15%
2022-09-30	$208.98M	37.15%
2022-06-30	$152.37M	29.92%
2022-03-31	$117.28M	14.98%
2021-12-31	$102.00M	-11.94%
2021-09-30	$115.83M	-15.11%
2021-06-30	$136.46M	53.28%
2021-03-31	$89.02M	-26.85%
2020-12-31	$121.70M	86.33%
2020-09-30	$65.32M	18.28%
2020-06-30	$55.22M	117.80%
2020-03-31	$25.35M	-52.76%
2019-12-31	$53.66M	16.08%
2019-09-30	$46.23M	18.09%
2019-06-30	$39.15M	-31.26%
2019-03-31	$56.95M	-5.45%
2018-12-31	$60.23M	135.69%
2018-09-30	$25.56M	-27.40%
2018-06-30	$35.20M	14.03%
2018-03-31	$30.87M	-83.71%
2017-12-31	$189.56M	197.44%
2017-09-30	$63.73M	88.83%
2017-06-30	$33.75M	14.14%
2017-03-31	$29.57M	-24.19%
2016-12-31	$39.00M	22.45%
2016-09-30	$31.85M	-4.45%
2016-06-30	$33.34M	-21.56%
2016-03-31	$42.50M	-18.63%
2015-12-31	$52.23M	151.33%
2015-09-30	$20.78M	-52.10%
2015-06-30	$43.38M	132.42%
2015-03-31	$18.67M	-38.55%
2014-12-31	$30.38M	107.98%
2014-09-30	$14.61M	-20.55%
2014-06-30	$18.39M	53.64%
2014-03-31	$11.97M	-4.26%
2013-12-31	$12.50M	-21.95%
2013-09-30	$16.01M	10.79%
2013-06-30	$14.45M	22.14%
2013-03-31	$11.83M	-45.70%
2012-12-31	$21.79M	308.55%
2012-09-30	$5.33M	-31.23%
2012-06-30	$7.76M	4.26%
2012-03-31	$7.44M	208.57%
2011-12-31	$2.41M	-89.49%
2011-09-30	$22.94M	-1.06%
2011-06-30	$23.19M	207.39%
2011-03-31	$7.54M	111.16%
2010-12-31	$3.57M	5.18%
2010-09-30	$3.40M	5.70%
2010-06-30	$3.21M	-6.64%
2010-03-31	$3.44M	-46.59%
2009-12-31	$6.44M	112.75%
2009-09-30	$3.03M	112.38%
2009-06-30	$1.43M	-48.56%
2009-03-31	$2.77M	-9.46%
2008-12-31	$3.06M	24.37%
2008-09-30	$2.46M	71.68%
2008-06-30	$1.43M	-20.56%
2008-03-31	$1.81M	34.95%
2007-12-31	$1.34M	-

Halozyme Therapeutics generated $290.08M in revenue during Q3 2024, up 25.39% compared to the previous quarter, and up 131.24% compared to the same period a year ago.

Halozyme Therapeutics Revenue Breakdown

Halozyme Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Bulk rHuPH20	$86.33M	$115.44M	-	-	-
Product	$303.49M	$300.85M	$191.03M	$104.22M	$55.99M
Collaborative Agreements	$140.84M	$80.53M	$108.61M	$135.19M	$123.01M
Royalty	$570.99M	$447.87M	$360.48M	$203.90M	$88.60M
Sales-based milestone	$30.00M	-	$10.00M	$50.00M	$15.00M
Upfront Fees	$27.00M	-	-	-	-
Research and Development Services	-	$9.53M	$9.61M	$1.19M	$1.25M
Upfront fees	-	$2.00M	$30.00M	$42.00M	$37.26M
bulk rHuPH20	-	-	$82.08M	$80.96M	$38.24M
Development Fees	-	-	$59.00M	$42.00M	$69.50M
Hylenex Recombinant	-	-	-	$23.26M	$17.03M
ENHANZE drug product	-	-	-	-	$719.00K

Halozyme Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Royalty (49.28%), Product (26.19%), Collaborative Agreements (12.16%), Bulk rHuPH20 (7.45%), Sales-based milestone (2.59%), and Upfront Fees (2.33%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Product	$144.13M	$86.66M	$72.70M	$79.60M	$86.57M	$73.89M	$60.79M	$61.16M	$61.43M	$46.30M	$22.14M	$25.05M	$30.36M	$21.77M	$32.45M	$9.05M	$6.34M	$8.15M	$22.69M	$29.20M
Royalty	$295.34M	$155.06M	$120.59M	$122.05M	$114.43M	$111.74M	$99.64M	$105.98M	$99.55M	$85.34M	$69.61M	$58.56M	$45.78M	$36.92M	$32.00M	$23.93M	$15.85M	$16.82M	$17.23M	$16.61M
Collaborative Agreements	$75.77M	$48.36M	$16.70M	$28.39M	$15.03M	$35.41M	$1.71M	$14.35M	$48.00M	$20.73M	$25.53M	$32.22M	$60.32M	$30.33M	$57.25M	$32.34M	$33.04M	$385.00K	$13.74M	$416.00K
Upfront fees	-	$27.00M	-	-	-	-	-	$5.00M	$25.00M	$2.00M	$40.00M	$30.00M	-	$7.26M	-	$13.00M	-	-	-	-
bulk rHuPH20	-	$31.49M	$10.51M	$37.00M	$27.13M	$22.07M	$21.32M	$19.26M	$25.06M	$16.45M	$18.86M	$24.06M	$16.77M	$26.71M	$3.85M	$3.91M	$3.77M	$17.14M	$24.59M	-
Development Fees	-	-	-	-	-	-	-	-	$44.00M	$15.00M	-	-	-	$30.00M	$12.00M	$32.00M	$25.50M	-	$500.00K	-
Sales-based milestone	-	-	-	-	-	-	-	-	-	-	$30.00M	$20.00M	-	-	-	-	-	-	-	-
Research and Development Services	-	-	-	-	-	-	-	-	-	-	$534.00K	$220.00K	$317.00K	$333.00K	$251.00K	$337.00K	$274.00K	$385.00K	$242.00K	$416.00K
Hylenex Recombinant	-	-	-	-	-	-	-	-	-	-	$5.69M	$6.18M	$6.27M	$5.00M	$5.46M	$4.94M	$2.29M	$4.33M	$5.45M	$4.27M
ENHANZE drug product	-	-	-	-	-	-	-	-	-	-	-	-	$24.00K	-	$281.00K	$254.00K	$138.00K	$46.00K	$99.00K	$344.00K
License Fees And Event-Based	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$55.90M	$40.80M	-	-	-

Halozyme Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Royalty (57.32%), Product (27.97%), and Collaborative Agreements (14.71%).

Halozyme Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 18
UNITED STATES	$40.48M
SWITZERLAND	$109.89M

Halozyme Therapeutics's latest annual revenue breakdown by geography, as of Dec 18: SWITZERLAND (73.08%), and UNITED STATES (26.92%).

Halozyme Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BMRN	BioMarin Pharmaceutical	$2.85B	$733.87B
BGNE	BeiGene	$2.46B	$929.17M
ALNY	Alnylam Pharmaceuticals	$2.25B	$420.15M
EXEL	Exelixis	$2.17B	$478.06M
HALO	Halozyme Therapeutics	$1.02B	$290.08M
APLS	Apellis Pharmaceuticals	$709.95M	$176.57M
RARE	Ultragenyx Pharmaceutical	$560.23M	$147.03M
BPMC	Blueprint Medicines	$508.82M	$128.18M
INSM	Insmed	$363.71M	$93.42M
LEGN	Legend Biotech	$285.14M	$93.99M
ASND	Ascendis Pharma	$266.72M	$95.89M
ALEC	Alector	$100.56M	$15.08M
AGIO	Agios Pharmaceuticals	$36.50M	$8.96M
CYTK	Cytokinetics	$18.47M	$463.00K
INBX	Inhibrx Biosciences	$200.00K	-
PTGX	Protagonist Therapeutics	-	$4.67M
VRDN	Viridian Therapeutics	-	$86.00K
EWTX	Edgewise Therapeutics	-	-
LRMR	Larimar Therapeutics	-	-

HALO Revenue FAQ

What is Halozyme Therapeutics’s yearly revenue?

Halozyme Therapeutics's yearly revenue for 2024 was $1.02B, representing an increase of 22.44% compared to 2023. The company's yearly revenue for 2023 was $829.25M, representing an increase of 25.62% compared to 2022. HALO's yearly revenue for 2022 was $660.12M, representing an increase of 48.91% compared to 2021.

What is Halozyme Therapeutics’s quarterly revenue?

Halozyme Therapeutics's quarterly revenue for Q3 2024 was $290.08M, a 25.39% increase from the previous quarter (Q2 2024), and a 34.28% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $231.35M, a 18.11% increase from the previous quarter (Q1 2024), and a 4.67% increase year-over-year (Q2 2023). HALO's quarterly revenue for Q1 2024 was $195.88M, a -14.85% decrease from the previous quarter (Q4 2023), and a 20.81% increase year-over-year (Q1 2023).

What is Halozyme Therapeutics’s revenue growth rate?

Halozyme Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 53.81%, and for the last 5 years (2020-2024) was 279.43%.

What are Halozyme Therapeutics’s revenue streams?

Halozyme Therapeutics's revenue streams in c 24 are Bulk rHuPH20, Product, Collaborative Agreements, Royalty, Sales-based milestone, and Upfront Fees. Bulk rHuPH20 generated $86.33M in revenue, accounting 7.45% of the company's total revenue, down -25.21% year-over-year. Product generated $303.49M in revenue, accounting 26.19% of the company's total revenue, up 0.88% year-over-year. Collaborative Agreements generated $140.84M in revenue, accounting 12.16% of the company's total revenue, up 74.88% year-over-year. Royalty generated $570.99M in revenue, accounting 49.28% of the company's total revenue, up 27.49% year-over-year. Sales-based milestone generated $30M in revenue, accounting 2.59% of the company's total revenue Upfront Fees generated $27M in revenue, accounting 2.33% of the company's total revenue

What is Halozyme Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Halozyme Therapeutics was Royalty. This segment made a revenue of $570.99M, representing 49.28% of the company's total revenue.